Innovative
Monoclonal Antibodies
Against Small Molecules
& Transmembrane Proteins

GPCR therapeutic monoclonal antibodies

GPCR therapeutic monoclonal antibodies · 11. September 2021

C3a and C5a anaphylatoxin receptors, therapeutic GPCR targets of the complement system

SYnAbs unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR and C5aR GPCR. Functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.

GPCR therapeutic monoclonal antibodies · 14. August 2021

Orphan GPCR and their untapped therapeutic potential: the next wave of antibody drug targets?

Untapped therapeutic potential of orphan GPCR and SYnAbs functional monoclonals anti-GPCR. Generation of new antibody therapeutics targeting orphan membrane receptors.

GPCR therapeutic monoclonal antibodies · 30. June 2021

CC chemokine receptors: latest news on Beta chemokine receptor therapeutics

SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to modified peptides, DNA and cell immunization strategies

GPCR therapeutic monoclonal antibodies · 10. June 2021

Chemokine receptors: a promising GPCR family to target?

SYnAbs develops anti-chemokine receptors monoclonal antibodies with therapeutic effect for Biotech and Pharma companies

GPCR therapeutic monoclonal antibodies · 14. December 2020

How does GPCR move? Learn the dynamics of the seven-(pass)-transmembrane domain receptors

Molecular dynamics of G protein-coupled receptors (GPCRs) and unique monoclonal antibody effectors and binders targeting GPCR.

GPCR therapeutic monoclonal antibodies · 05. October 2020

History of GPCR and GPCR antibodies

SYnabs develops anti-GPCR stereo-specific monoclonal antibodies for Pharma and biotech companies thanks to unique proprietary DNA and cell immunization technologies